Citation Impact 2023
Source Normalized Impact per Paper (SNIP): 0.893
SCImago Journal Rank (SJR): 0.475
Usage 2023
Downloads: 640,615
Altmetric mentions: 196
Volume 2 Supplement 2
Edited by Aldo Castagnari
Publication of this supplement was supported by Laboratorios Roche Syntex MĆ©xico
Experts Meeting on Lung Cancer and the Use of Erlotinib.
New York, USA10 November 2007
Lung cancer is the leading cause of cancer-related deaths among males and the second among females. The importance of lung cancer is a major public health problem and there is a need to find effective therapie...
Treatment of non-small-cell lung cancer is dependent on disease stage. For patients with metastasis or locally advanced disease, the importance of finding therapeutic schemes that may benefit this population i...
During the Experts Meeting on Lung Cancer, participants emphasized the usefulness of erlotinib as second-line therapy for lung cancer. They noted that, although there are no comparative studies, erlotinib coul...
Citation Impact 2023
Source Normalized Impact per Paper (SNIP): 0.893
SCImago Journal Rank (SJR): 0.475
Usage 2023
Downloads: 640,615
Altmetric mentions: 196